Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 4.53M | 4.26M | 4.15M | 3.84M | 3.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.53M | 4.26M | 4.15M | 3.84M | 3.90M |
| Cost of Revenue | 2.35M | 2.17M | 1.68M | 1.64M | 1.81M |
| Gross Profit | 2.18M | 2.10M | 2.47M | 2.20M | 2.09M |
| SG&A Expenses | 3.11M | 4.25M | 3.79M | 4.06M | 3.49M |
| Depreciation & Amortization | 523.60K | 634.90K | 972.30K | 766.40K | 716.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.75M | 7.39M | 6.82M | 7.23M | 9.77M |
| Operating Income | -2.23M | -3.13M | -2.67M | -3.40M | -5.88M |
| Income Before Tax | -1.91M | -2.87M | -4.35M | -3.41M | -5.62M |
| Income Tax Expenses | 23.60K | -196.40K | -566.30K | 77.20K | -94.70K |
| Earnings from Continuing Operations | -1.93M | -2.67M | -3.79M | -3.49M | -5.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.93M | -2.67M | -3.79M | -3.49M | -5.52M |
| EBIT | -2.23M | -3.13M | -2.67M | -3.40M | -5.88M |
| EBITDA | -1.82M | -2.13M | -1.82M | -3.07M | -4.78M |
| EPS Basic | -0.08 | -0.11 | -0.15 | -0.14 | -0.22 |
| Normalized Basic EPS | -0.05 | -0.07 | -0.06 | -0.09 | -0.14 |
| EPS Diluted | -0.08 | -0.11 | -0.15 | -0.14 | -0.22 |
| Normalized Diluted EPS | -0.05 | -0.07 | -0.06 | -0.09 | -0.14 |
| Average Basic Shares Outstanding | 25.05M | 25.05M | 25.03M | 24.94M | 24.87M |
| Average Diluted Shares Outstanding | 25.05M | 25.05M | 25.03M | 24.94M | 24.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |